Interferon Beta and Glatiramer Acetate Therapy

Neurotherapeutics

Volumn 10, Issue 1, 2013, Pages 2-18

  McGraw, Corey A ^a   Lublin, Fred D ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Glatiramer acetate; History; Interferon beta; Multiple sclerosis therapeutics; Review

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO;

ANTIBODY TITER; ARTHRALGIA; AUTOIMMUNE DISEASE; CHILL; COMORBIDITY; CROSS REACTION; DEMYELINATING DISEASE; DISEASE ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMATOMA; HUMAN; IMMUNE RESPONSE; MULTIPLE SCLEROSIS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SECONDARY INFECTION; SKIN ATROPHY; SKIN INFECTION; SKIN NECROSIS;

EID: 84873155845     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0163-4     Document Type: Review

References (103)

1. Derwenskus J, Lublin FD. Use of interferon-beta in the treatment of multiple sclerosis. Adv Neurol 2006; 98: 257-271.
2. McFarlin DE. Multiple sclerosis (second of two parts). N Engl J Med 1982; 307: 1246-1251.
3. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 18: 893-895.
4. Lublin F. History of modern multiple sclerosis therapy. J Neurol 2005; 252 (Suppl 3): iii3-iii9.
5. Knobler RL, Panitch HS, Braheny SL, et al. Systemic alpha-interferon therapy of multiple sclerosis. Neurology 1984; 34: 1273-1279.
6. Camenga DL, Johnson KP, Alter M, et al. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 1986; 43: 1239-1246.
7. AUSTIMS Research Group. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. J Neurol Neurosurg Psychiatry 1989; 52: 566-574.
8. Jacobs L, Salazar AM, Herndon R, et al. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 1986; 2: 1411-1413.
9. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012; 12: 125-135.
10. Schafer SL, Lin R, Moore PA, Hiscott J, Pitha PM. Regulation of type I interferon gene expression by interferon regulatory factor-3. J Biol Chem 1998; 273: 2714-2720.
11. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-264.
12. Sega S, Wraber B, Mesec A, Horvat A, Ihan A. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines. Clin Neurol Neurosurg 2004; 106: 255-258.
13. Kieseier BC. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 2011; 25: 491-502.
14. Mirandola SR, Hallal DE, Farias AS, et al. Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis. Int Immunopharmacol 2009; 9: 824-830.
15. Prat A, Biernacki K, Antel JP. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1. J Autoimmun 2005; 24: 119-124.
16. Graber JJ, McGraw CA, Kimbrough D, Dhib-Jalbut S. Overlapping and distinct mechanisms of action of multiple sclerosis therapies. Clin Neurol Neurosurg 2010; 112: 583-591.
17. Chiu AW, Richert N, Ehrmantraut M, et al. Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol 2009; 66: 39-43.
18. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebocontrolled trial. UBC MS/MRI study group and the IFNB multiple sclerosis study group. Neurology 1993; 43: 662-667.
19. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285.
20. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
21. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebocontrolled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
22. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsingremitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 1999; 46: 197-206.
23. The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS study. Neurology 1999; 53: 679-686.
24. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group. N Engl J Med 2000; 343: 898-904.
25. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582.
26. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249.
27. Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012; 11: 33-41.
28. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the "McDonald criteria". Ann Neurol 2011; 69: 292-302.
29. Pittock SJ. Interferon beta in multiple sclerosis: how much BENEFIT? Lancet 2007; 370: 363-364.
30. Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002; 51: 481-490.
31. Martinez-Yelamos S, Martinez-Yelamos A, Martin Ozaeta G, et al. Regression to the mean in multiple sclerosis. Mult Scler 2006; 12: 826-829.
32. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678-684.
33. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.
34. Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH. Disability as an outcome in MS clinical trials. Neurology 2008; 71: 624-631.
35. Healy B, Chitnis T, Engler D. Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies. J Neurol 2011; 258: 1812-1819.
36. Panitch H, Miller A, Paty D, Weinshenker B. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788-1795.
37. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-1504.
38. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-687.
39. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-882.
40. Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75: 706-710.
41. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44-51.
42. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59: 1496-1506.
43. Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE study. Arch Neurol 2005; 62: 785-792.
44. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460.
45. Koch-Henriksen N, Sorensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006; 66: 1056-1060.
46. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7: 903-914.
47. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009; 72: 1976-1983.
48. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009; 8: 889-897.
49. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol 2010; 9: 299-308.
50. Milo R, Panitch H. Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J Neuroimmunol. 1995; 61: 185-193.
51. Brod SA, Lindsey JW, Wolinsky JS. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann Neurol 2000; 47: 127-131.
52. Chen M, Gran B, Costello K, et al. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 2001; 7: 209-219.
53. Lublin F, Cofield S, Cutter G, et al. The CombiRx trial: a multi-center, doubleblind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing-remitting multiple sclerosis - clinical outcomes. Neurology 2012; 78: PL02. 003. Abstract.
54. Ravnborg M, Sørensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9: 672-680.
55. Sorensen PS, Mellgren SI, Svenningsson A, et al. NORdic trial of oral methylprednisolone as add-on therapy to interferon beta-1a for treatment of relapsingremitting multiple sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009; 8: 519-529.
56. Cohen JA, Imrey PB, Calabresi PA, et al. Results of the avonex combination trial (ACT) in relapsing-remitting MS. Neurology 2009; 72: 535-541.
57. Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010; 81: 907-912.
58. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 2012; 78: 1315-1322.
59. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler 2012; 18: 932-946.
60. Kremenchutzky M, Morrow S, Rush C. The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis. Expert Opin Drug Saf 2007; 6: 279-288.
61. Sormani MP, Stubinski B, Cornelisse P, et al. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler 2011; 17: 541-549.
62. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-555.
63. Killestein J, Polman CH. Determinants of interferon beta efficacy in patients with multiple sclerosis. Nat Rev Neurol 2011; 7: 221-228.
64. Hegen H, Schleiser M, Gneiss C, et al. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler 2012; 18: 610-615.
65. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9: 740-750.
66. Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010; 16: 406-412.
67. Bushnell SE, Zhao Z, Stebbins CC, et al. Serum IL-17F does not predict poor response to IM IFNbeta-1a in relapsing-remitting MS. Neurology 2012; 79: 531-537.
68. Reingold SC, Steiner JP, Polman CH, et al. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology 2009; 73: 552-559.
69. Arnon R. The development of Cop 1 (copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol Lett 1996; 50: 1-15.
70. Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsingremitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs 2010; 70: 1545-1577.
71. Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol 2008; 255: 26-36.
72. Hestvik AL, Skorstad G, Price DA, Vartdal F, Holmoy T. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid. Mult Scler 2008; 14: 749-758.
73. Webb C, Teitelbaum D, Herz A, Arnon R, Sela M. Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry 1976; 13: 333-337.
74. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4 + CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A 2005; 102: 6449-6454.
75. Teitelbaum D, Brenner T, Abramsky O, et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003; 9: 592-599.
76. Brenner T, Arnon R, Sela M, et al. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with copaxone. J Neuroimmunol 2001; 115: 152-160.
77. Lalive PH, Neuhaus O, Benkhoucha et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 2011; 25: 401-414.
78. Sarchielli P, Zaffaroni M, Floridi A, et al. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult Scler 2007; 13: 313-331.
79. Aharoni R, Eilam R, Domev H, et al. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A 2005; 102: 19045-19050.
80. Skihar V, Silva C, Chojnacki A, et al. Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci U S A 2009; 106: 17992-17997.
81. Abramsky O, Teitelbaum D, Arnon R. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report. J Neurol Sci 1977; 31: 433-438.
82. Bornstein MB, Miller AI, Teitelbaum D, Arnon R, Sela M. Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol 1982; 11: 317-319.
83. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbatingremitting multiple sclerosis. N Engl J Med 1987; 317: 408-414.
84. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group. Neurology 1995; 45: 1268-1276.
85. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 multiple sclerosis study group. Neurology 1998; 50: 701-708.
86. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000; 54: 813-817.
87. Mancardi GL, Sardanelli F, Parodi RC, et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 1998; 50: 1127-1133.
88. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian glatiramer acetate study group. Ann Neurol 2001; 49: 290-297.
89. Comi G. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. The Lancet (British edition) 2009; 374: 1503-1511.
90. Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991; 41: 533-539.
91. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14-24.
92. Wolinsky JS, Shochat T, Weiss S, Ladkani D, PROMiSe Trial Study Group. Glatiramer acetate treatment in PPMS: why males appear to respond favorably. J Neurol Sci 2009; 286: 92-98.
93. Tullman MJ, Lublin FD. Combination therapy in multiple sclerosis. Curr Neurol Neurosci Rep 2005; 5: 245-248.
94. Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci 2009; 277: S42-S45.
95. Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009; 72: 806-812.
96. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 multiple sclerosis study group. Mult Scler 2000; 6: 255-266.
97. Johnson KP, Ford CC, Lisak RP, Wolinsky JS. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 2005; 111: 42-47.
98. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006; 12: 309-320.
99. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010; 16: 342-350.
100. Rauschka H, Farina C, Sator P, et al. Severe anaphylactic reaction to glatiramer acetate with specific IgE. Neurology 2005; 64: 1481-1482.
101. Baumgartner A, Stich O, Rauer S. Anaphylactic reaction after injection of glatiramer acetate (copaxone(R)) in patients with relapsing-remitting multiple sclerosis. Eur Neurol 2011; 66: 368-370.
102. Filippi M, Wolinsky JS, Comi G, CORAL Study Group. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 2006; 5: 213-220.
103. De Stefano N, Filippi M, Confavreux C, et al. The results of two multicenter, openlabel studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis. Mult Scler 2009; 15: 238-243.